Literature DB >> 3328330

Amodiaquine fails to cure chloroquine resistant Plasmodium falciparum in the Punjab.

A A Khaliq1, E Fox, M Sarwar, G T Strickland.   

Abstract

We evaluated amodiaquine as a replacement drug for treating falciparum malaria in an area of Pakistani Punjab where chloroquine-resistant Plasmodium falciparum has recently emerged. Amodiaquine appeared to be 4 to 8 times more effective than chloroquine when P. falciparum isolates were tested in vitro. However, the recrudescence rate was greater than 50% after oral treatment with 20 mg/kg amodiaquine given over two successive days. This lack of therapeutic response from amodiaquine may have been due to selection of resistant parasites in the villages where the study was performed through extensive use of chloroquine for presumptive malaria treatment during the preceding 18 months. We conclude that amodiaquine is not a suitable replacement for chloroquine for treating falciparum malaria in our study area despite in vitro sensitivity data suggesting that it would be efficacious. Baseline in vitro sensitivity to mefloquine is also reported.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3328330     DOI: 10.1016/0035-9203(87)90311-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  3 in total

1.  Amodiaquine resistance in Plasmodium falciparum malaria in Afghanistan is associated with the pfcrt SVMNT allele at codons 72 to 76.

Authors:  Khalid Beshir; Colin J Sutherland; Ioannis Merinopoulos; Naeem Durrani; Toby Leslie; Mark Rowland; Rachel L Hallett
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 2.  Treatment of malaria--1990.

Authors:  D M Panisko; J S Keystone
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

3.  The disposition of amodiaquine in Zambians and Nigerians with malaria.

Authors:  P A Winstanley; O Simooya; J M Kofi-Ekue; O Walker; L A Salako; G Edwards; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.